Appeals court ruling blocks Lyrica competition until 2018

10-02-2014

Appeals court ruling blocks Lyrica competition until 2018

Photo: Rob Wilson / Shutterstock.com

The US Court of Appeals for the Federal Circuit has upheld a patent covering Pfizer’s pain drug Lyrica, closing the market to any generic challengers until 2018.


Pfizer, Lyrica, Mylan, Teva, US Court of Appeals for the Federal Circuit

LSIPR